Qubit Pharmaceuticals, a deeptech company specializing in the discovery of new drug candidates through simulation and molecular modeling accelerated by hybrid HPC and quantum computing, announces that it has been nominated for the Prix Galien USA “Best Startup Award”. This nomination is in line with Qubit Pharmaceuticals’ strategic commitment to establishing and expanding its activities in North America, a key market for biomedical and pharmaceutical research.
Awarded by the Fondation Galien, the world’s leading institution for honoring innovators in the field of life sciences, the Prix Galien is considered the equivalent of the Nobel Prize in biopharmaceutical research. First introduced in France in 1970, the Prix Galien is now awarded in 17 countries, including the United States since 2007. Each year, it recognizes outstanding innovations that contribute to improving the quality of public healthcare. Organized in partnership with Business France, the Startup category, which is celebrating its tenth anniversary, is designed to reward innovative French and international startups with a strong societal impact that are collaborating with an American entity in the Pharma, BioTech and Medtech fields. Prix Galien USA aims to raise the profile of startups and promote transatlantic partnerships with government, industry and academia.
As a nominee, Qubit Pharmaceuticals will participate in industry meetings, workshops and conferences around the US healthcare ecosystem to explore potential strategies for development in North America. The Startup Award ceremony will take place on November 7 at the Museum of Natural History in New York.
Robert Marino, CEO Qubit Pharmaceuticals, states : “We are extremely pleased to be nominated for this prestigious award. Beyond the sense of pride, this recognition once again underlines the excellence of our technology, and will be a powerful source of visibility in the U.S. for potential international partnerships”.
Accelerating drug discovery with hybrid HPC and quantum computing
With a team of 60 specialists in quantum chemistry, computational chemistry, machine-learning and medicinal chemistry, and thanks to the hybrid use of HPC (High Performance Computing) supercomputers and quantum algorithms, Qubit Pharmaceuticals has developed its revolutionary drug discovery software platform, Atlas, which aims to reduce by a factor of 2 the time needed to screen, select and optimize a drug candidate of interest, and by a factor of more than 10 the investment required. Qubit Pharmaceuticals manages a portfolio of 7 drug discovery programs, with a focus on targets recognized as complex in fields such as oncology and chronic inflammatory diseases. Qubit Pharmaceuticals also has an innovative program focused on the discovery of new treatments using RNA.
